An Innovative Unbiased Binding
Compared to other technologies, we optimize the capture of exosomes with our patented compounds.
Our technology is based on the capture of extracellular vesicles (microvesicles and exosomes) with our patented novel lead compound.
By not targeting a specific biomarker and with a simpler laboratory process which preserves the integrity of exosomes, we provide a broader set of applications both for diagnostic and therapeutic purposes, across multiple health conditions.
DIABETIC NEPHROPATHY
Detection of the biomarker podocalyxin from exosome collected with our technology from the urine of people with diabetic nephropathy.
PEOPLE WITH DIABETES, NORMOALBUMINURIA AND MACROALBUNINURIA
Our technology detects CD41, a biomarker located in exosomes and microvesicles, in plasma from people with diabetes, normoalbuminuria and macroalburninuria.
What are Exostatics?
Exosomes function to transmit information between cells. Exosomes can transfer substances, including proteins, lipids, metabolites, RNA, mitochondrial DNA, and even activated receptors, to recipient cells, which affects the signaling pathways of the recipient cells, consequently modulating protein expression and phenotype.
Want To Start Investing With Us?
Investing in the novel technology of Exostatics can help accelerating the development of innovative solutions addressing potentially life-threatening conditions.